Company intelligence / Profile preview

SQZ Biotechnologies

Ownership: Private
Employees: ~9
Development stage: Other

Overview

SQZ Biotechnologies developed a novel platform for engineering immune cells using mechanical deformation. The company advanced several programs into early clinical trials, including antigen-presenting cell therapies for oncology indications such as HPV16+ solid tumors. Despite promising science and major partnerships with Roche, financial difficulties led to delisting from the NYSE in 2023 and eventual acquisition by STEMCELL Technologies in February 2024[2][6].

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyPlatform technology (CellSqueeze)
Industry: Biotech

Partnerships

Roche (2015–2023; oncology/cell therapies partnership worth up to $1B)

Beyond the preview

Go deeper on SQZ Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQZ Biotechnologies.

Explore the full profile